Probiotics are suggested to have beneficial effects in atopic dermatitis (AD) treatment and prevention but their precise role is not yet clear. The aim of this randomized double blinded active treatment vs placebo study was to evaluate clinical efficacy of intake of a combination of two probiotics (Lactobacillus salivarius LS01 and Bifidobacterium breve BR03) for the treatment of adult AD patients. The rationale for the use of probiotics in the treatment of atopic dermatitis would be due to some experimental hypotheses: 1. The use of these microbial agents at an early age seems to play an important role in inducing immunity T type 1 (Th1) and inhibit the development of a Th2 response IgE mediated 2. the normal intestinal flora (including probiotics) would play an important role in inducing immunological tolerance 3. the hygiene hypothesis that the reduced bacterial environment would favour a type 2 response T and the development of allergic diseases
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
48
a mixture of Lactobacillus LS01 DSM 2275 and Bifidobacterium BR03 DSM 16604 at a dose of 1 x 109 colony forming units (CFU)/g each in maltodextrin
sachets
Luigi Sacco Hospital
Milan, Italy
clinical effects of probiotics on adult atopic dermatitis
To evaluate the clinical course of adult patients affected by atopic dermatitis after the intake of two probiotics vs placebo
Time frame: 20 weeks
effects of probiotics on immune system and faecal microbiota in adult atopic dermatitis
to evaluate these parameters: percentage of circulating Treg cells, percentage of Th17 cells, Th1 and Th2, percentage of Treg cells TLR2+, TLR4 + and TLR9 +, Quantization plasma LPS. Determination by gene amplification and culture of Lactobacillus salivarius and Bifidobacterium in the faeces of the two groups studied
Time frame: 20 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.